Molecular pathology and molecular pharmacology of osteosarcoma

Pediatric Pathology and Molecular Medicine

Volumn 19, Issue 5, 2000, Pages 391-413

  Ladanyi, M ^a   Gorlick, R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cyclin dependent kinase (CDK); Retinoblastoma (RB)

Indexed keywords

CISPLATIN; CYCLIN D1; DOXORUBICIN; IFOSFAMIDE; METHOTREXATE; PROTEIN P16; PROTEIN P53;

ARTICLE; CANCER CHEMOTHERAPY; CHROMOSOME BANDING PATTERN; GENE AMPLIFICATION; GENE EXPRESSION; GENE STRUCTURE; GENETIC CODE; HUMAN; MOLECULAR BIOLOGY; MOLECULAR CLONING; MULTIDRUG RESISTANCE; ONCOGENE C FOS; ONCOGENE MYC; ONCOGENE NEU; OSTEOSARCOMA; PRIORITY JOURNAL; PROGNOSIS; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

EID: 0033693273     PISSN: 15227952     EISSN: None     Source Type: Journal    
DOI: 10.1080/15513810009168647     Document Type: Article

References (149)

1. Chemotherapy for nonmetastatic osteogenic sarcoma: The Memorial Sloan-Kettering experience
2. Osteogenic sarcoma with clinically detectable metastasis at initial presentation
3. Osteosarcoma
4. Contribution of molecular genetic data to the classification of sarcomas
5. Role of the RB/E2F pathway in cell growth control
6. Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer
7. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk
8. Involvement of the retinoblastoma gene in primary osteosarcomas and other bone and soft-tissue tumors
9. Analysis of alterations in the retinoblastoma gene and tumor grade in bone and soft-tissue sarcomas
10. Mutation spectrum of the retinoblastoma gene in osteosarcomas
11. Alterations of the P53, RB and MDM2 genes in osteosarcoma
12. Loss of heterozygosity and microsatellite instability at the retinoblastoma locus in osteosarcomas
13. Studies of the RB1 gene and the P53 gene in human osteosarcomas
14. Allelotype analysis in osteosarcomas: Frequent allele loss on 3q, 13q, 17p, and 18q
15. Alternative reading frames of the INK4A tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest
16. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas. Relationship to amplification and mRNA levels of CDK4 and cyclin D1
17. Alterations of the p15, p16, and p18 genes in osteosarcoma
18. CDK4 gene amplification in osteosarcoma: Reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons
19. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated
20. A cell cycle regulator potentially involved in genesis of many tumor types
21. Gains and losses of DNA sequences in osteosarcomas by comparative genomic hybridization
22. Mutation of cell cycle regulators. Biological and clinical implications for human neoplasia
23. Amplification of the CDK4 gene in sarcomas. Tumor specificity and relationship with the RB gene mutation
24. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas
25. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas
26. MDM2 and CDK4 gene amplification in Ewing's sarcoma
27. HMGIC, the gene for an architectural transcription factor, is amplified and rearranged in a subset of human sarcomas
28. Molecular cytogenetic characterization and physical mapping of 12q13-15 amplification in human cancers
29. Refined mapping of 12q13-q15 amplicons in human malignant gliomas suggests CDK4/SAS and MDM2 as independent amplification targets
30. Complexity of 12q13-22 amplicon in liposarcoma: Microsatellite repeat analysis
31. No p16(INK4A)/CDKN2/MTS1 mutations independent of P53 status in soft tissue sarcomas
32. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations
33. Regulation of P53 downstream genes
34. P53, the cellular gatekeeper for growth and division
35. P53: From inductive signal to cellular effect
36. Mutation spectrum of the P53 gene in bone and soft tissue sarcomas
37. MDM2 gene amplification in metastatic osteosarcoma
38. P53 and MDM2 alterations in osteosarcomas: Correlation with clinicopathologic features and proliferative rate
39. Tumor spectrum analysis in P53-mutant mice
40. Germ line P53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms
41. Germ-line transmission of a mutated P53 gene in a cancer-prone family with Li-Fraumeni syndrome
42. Germline mutations of the P53 tumor suppressor gene in children with osteosarcoma
43. Prevalence and spectrum of germline mutations of the P53 gene among patients with sarcoma
44. Regulation of the P53 protein by the MDM2 oncoprotein
45. Amplification of a gene encoding a P53-associated protein in human sarcomas
46. Oncoprotein MDM2 conceals the activation domain of tumour suppressor P53
47. The MDM2 gene amplification database
48. p16INK4A: A gene with a dual capacity to encode unrelated proteins that inhibit cell cycle progression
49. Splicing into senescence: The curious case of p16 and p19(ARF)
50. The INK4A tumor suppressor gene product, p16(ARF), interacts with MDM2 and neutralizes MDM2's inhibition of P53
51. ARF promotes MDM2 degradation and stabilizes P53: ARF-INK4A locus deletion impairs both the RB and P53 tumor suppression pathways
52. P19(ARF) stabilizes P53 by blocking nucleo-cytoplasmic shuttling of MDM2
53. Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma
54. Association of loss of heterozygosity at the P53 locus with chemoresistance in osteosarcoma
55. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: Preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, MDM2
56. Amplification of the gli gene in childhood sarcomas
57. Identification and cloning of a novel amplified DNA sequence in human malignant fibrous histiocytoma derived from a region of chromosome 12 frequently rearranged in soft tissue tumors
58. Characterization of a highly conserved gene (OS4) amplified with CDK4 in human sarcomas
59. Complete sequence analysis of a gene (OS-9) ubiquitously expressed in human tissues and amplified in sarcomas
60. Amplifications of DNA primase 1 (PRIM1) in human osteosarcoma
61. Isolation of genes amplified in human cancers by microdissection mediated cDNA capture
62. Transcript mapping in a 46-kb sequenced region at the core of 12q13.3 amplification in human cancers
63. SAS, a gene amplified in human sarcomas, encodes a new member of the transmembrane 4 superfamily of proteins
64. Coamplification and overexpression of CDK4, SAS and MDM2 occurs frequently in human parosteal osteosarcomas
65. Ring chromosomes in parosteal osteosarcoma contain sequences from 12q13-15: A combined cytogenetic and comparative genomic hybridization study
66. Comparative genomic hybridization of low-grade central osteosarcoma
67. Analysis of SAS gene and CDK4 and MDM2 proteins in low-grade osteosarcoma
68. Molecular characterization of a novel amplicon at lq21-q22 frequently observed in human sarcomas
69. Comparative genomic hybridization analysis of human sarcomas: II. Identification of novel amplicons at 6p and 17p in osteosarcomas
70. DNA sequence copy number increase at 8q: A potential new prognostic marker in high-grade osteosarcoma
71. Malignant astrocytoma-derived region of common amplification in chromosomal band 17p12 is frequently amplified in high-grade osteosarcomas
72. Isolation of osteosarcoma-associated amplified DNA sequences using representational difference analysis
73. Localization of a novel tumor suppressor locus on human chromosome 3q important in osteosarcoma tumorigenesis
74. Evidence for a novel osteosarcoma tumor-suppressor gene in the chromosome 18 region genetically linked with Paget disease of bone
75. A novel chromosomal region of allelic loss, 4q32-q34, in human osteosarcomas revealed by representational difference analysis
76. SV40-like sequences in human bone tumors
77. Cell and molecular biology of simian virus 40: Implications for human infections and disease
78. Integration of SV40 in human osteosarcoma DNA
79. The MYC oncoprotein: A critical evaluation of trans-activation and target gene regulation
80. MYC oncogenes and human neoplastic disease
81. Sporadic amplification of the MYC gene in human osteosarcomas
82. Amplification of the MYC gene in osteosarcoma arising in Paget's disease
83. c-MYC and FOS in human osteosarcoma. Prognostic value of mRNA and protein expression
84. FOS-induced osteosarcoma formation in transgenic mice: Cooperativity with c-jun and the role of endogenous FOS
85. FOS expression induces bone tumors in transgenic mice
86. The proto-oncogene FOS is overexpressed in the majority of human osteosarcomas
87. Immunohistochemical detection of FOS and c-jun expression in cartilaginous tumours of the skeleton
88. Oncogene alterations in primary, recurrent and metastatic human bone tumors
89. ErbB-2 expression is correlated with poor prognosis for patients with osteosarcoma
90. Expression of HER2/ErbB-2 correlates with survival in osteosarcoma
91. The Met/HGF receptor is overexpressed in human osteosarcomas and is activated by either a paracrine or autocrine circuit
92. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors
93. Expression of c-met proto-oncogene product in benign and malignant bone tumors
94. Met expression and sarcoma tumorigenecity
95. Redundancy of autocrine loops in human osteosarcoma cells
96. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma
97. Intrinsic and acquired resistance to methotrexate in acute leukemia
98. Ode to methotrexate
99. Preoperative chemotherapy for osteogenic sarcoma: Selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy
100. Primary osteogenic sarcoma. Pathologic aspects in 20 patients after treatment with chemotherapy, en bloc resection and prosthetic bone replacement
101. Neoadjuvant chemotherapy of osteosarcoma: Results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histologic tumor response
102. Intensification of preoperative chemotherapy for osteogenic sarcoma: The results of the Memorial Sloan-Kettering (T12) protocol
103. High-dose methotrexate in osteogenic sarcoma
104. Isolation of tumor cells from patients with osteosarcoma and analysis of their sensitivity to methotrexate
105. Dose escalation with pharmacokinetics monitoring in methotrexate chemotherapy of osteosarcoma
106. Methotrexate pharmacokinetics and prognosis in osteosarcoma
107. Serum methotrexate (MTX) concentrations and prognosis in patients with osteosarcoma of the extremities treated with a multidrug neoadjuvant regimen
108. Predictive factors of histologic response to primary chemotherapy in osteosarcoma of the extremity: Study of 272 patients preoperatively treated with high-dose methotrexate, doxorubicin, and cisplatin
109. Prognostic significance of chemotherapy dosage characteristic in children with osteogenic sarcoma
110. Mechanisms of methotrexate resistance in osteosarcoma
111. Expression of p-glycoprotein in high-grade osteosarcomas in relation to clinical outcome
112. p-Glycoprotein and metallotionein expression and resistance to chemotherapy in osteosarcoma
113. p-Glycoprotein expression in high grade central osteosarcoma and normal bone cells. An immunohistochemical study
114. p-Glycoprotein expression. Critical determinant in the response to osteosarcoma chemotherapy
115. Quantitative analysis of multidrug resistance gene expression in human osteosarcomas
116. MDR1 gene expression and outcome in osteosarcoma: A prospective, multicenter study
117. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs
118. Biology of the multidrug-associated protein, MRP
119. Topoisomerases, new targets in cancer chemotherapy
120. 1 to S phase transition
121. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes and apoptosis
122. Absence of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines
123. Role of E2F-1 in chemosensitivity
124. Effect of cyclin D1 overexpression on drug sensitivity in a human fibrosarcoma cell line
125. P53 status and the efficacy of cancer therapy in vivo
126. Transfection of wild-type but not mutant P53 induces early monocytic differentiation in HL60 cells and increases their sensitivity to stress
127. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type P53
128. Wild-type P53 restores cell cycle control and inhibits gene amplification in cells with mutant P53 alleles
129. Amplification and organization of dihydrofolate reductase genes in a human leukemia cell line, K-562, resistant to methotrexate
130. Dihydrofolate reductase as a therapeutic target
131. Tumor size and prognosis in aggressively treated osteosarcoma
132. Prognostic significance of serum lactate dehydrogenase in patients with osteosarcoma of the extremities
133. Prognostic value of serum alkaline phosphatase in osteosarcoma
134. Multidrug resistance and malignancy in human osteosarcoma
135. The expression of p-glycoprotein is causally related to a less aggressive phenotype in human osteosarcoma cells
136. p-Glycoprotein and multidrug resistance
137. MDR1 gene expression: Evaluation of its use as a molecular marker for prognosis and chemotherapy of bone and soft tissue sarcomas
138. Multidrug resistance in acute leukemia: A comparison of different diagnostic methods
139. Measuring multidrug resistance expression in human malignancies: Elaboration of consensus recommendations
140. Methods to detect p-glycoprotein-associated multidrug resistance in patients' tumors: Consensus recommendations
141. Correlation of p-glycoprotein detection by immunohistochemistry with mdr-1 mRNA levels in osteosarcomas
142. Relationship between p-glycoprotein positivity, doxorubicin binding ability and histologic response to chemotherapy in osteosarcomas
143. Cellular DNA content in human osteosarcoma. Aspects on diagnosis and prognosis
144. Prognostic significance of DNA ploidy pattern in osteosarcomas in association with chemotherapy
145. Prognostic significance of bone morphogenetic activity in osteosarcoma tissue
146. Expression of genes encoding bone morphogenetic proteins and their receptors in sarcomas
147. Expression of the smooth muscle calponin gene in human osteosarcoma and its possible association with prognosis
148. Clinical relevance of Ki-67 expression in bone tumors
149. Expression of transforming growth factor-β (TGF-β) isoforms in osteosarcomas